Enzo Biochem reports Q4 adjusted EPS (4c), one estimate (6c)
Reports Q4 revenue $26.6M, one estimate $26M. "Fiscal 2016 was a highly successful year for Enzo Biochem," said Enzo president Barry Weiner. "We solidified our growth opportunities on every front, setting a strong foundation for the future. Life Sciences' product development emphasis on high profit margin products is paying off with several key approvals awarded in 2016. Enzo Labs came off a strong year with solid forward momentum from its expanding line of innovative molecular diagnostics, especially in the women's health category, and a growing client roster. The unique combination of our Life Sciences development and marketing team with our Clinical Labs' hands-on testing capabilities, and our deep patent estate, has resulted in a formidable development program, to prepare our broad pipeline of products for regulatory approval."